Effect of angiotensin converting enzyme inhibitor enalapril on body weight and composition in young rats

Santos, Edson Lucas dos; Souza, Kely de Picoli; Guimarães, Paola Bianchi; Reis, Felipe C.G.; Silva, Sylvia Maria Affonso; Costa-Neto, Cláudio M.; Luz, Jacqueline; Pesquero, João Bosco

doi:10.1016/j.intimp.2007.07.021

Cited by 51 publications

(41 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This was important since rats fed ACE inhibitors are known to reduce their energy intake [31]. Fructose diet groups received 21 g/day (75.6 kcal/day) and normal control diet groups received 22.2 g/day (75.5 kcal/day), which is 20% less than the normal dietary intake we have historically observed [5].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Combination of Captopril and Allopurinol Retards Fructose-Induced Metabolic Syndrome

et al. 2009

View full text Add to dashboard Cite

Background: Both ACE inhibitors and allopurinol have been shown to partially prevent metabolic syndrome induced by fructose. We tested the hypothesis that combined therapy might be more effective at blocking the metabolic syndrome induced with fructose. Methods: Male Sprague-Dawley rats were fed a high fructose diet with or without allopurinol, captopril, or the combination for 20 weeks. A control group received a normal diet. All groups were pair-fed to assure equivalent caloric intake. Results: Despite reduced energy intake, the fructose-fed rats developed features of metabolic syndrome including elevated blood pressure, abdominal obesity, hypertriglyceridemia, hyperuricemia and hyperinsulinemia. While both allopurinol and captopril alone tended to reduce features of the metabolic syndrome, the combined therapy was synergistic, with significant reduction in blood pressure, less accumulation of abdominal fat, an improvement in the dyslipidemia and a complete prevention of insulin resistance. Conclusion: A high fructose diet can induce metabolic syndrome even in the setting of caloric restriction. Captopril and allopurinol synergistically reduce features of the metabolic syndrome, especially hypertension, insulin resistance and dyslipidemia. Combination allopurinol and ACE inhibitor therapy might provide a superior means to prevent diabetes and cardiovascular disease.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Since ACE inhibitors significantly reduce caloric intake in rats [31], rats were pair-fed to assure equivalent caloric intake. Body weight and water intake were measured weekly.…”

Section: Methodsmentioning

confidence: 99%

Combination of Captopril and Allopurinol Retards Fructose-Induced Metabolic Syndrome

et al. 2009

View full text Add to dashboard Cite

show abstract

“…It is clear that Ang II/AT 1 blockers (ACE inhibitors and Ang II receptor blockers) can prevent atherosclerosis and decrease cholesterol and triglyceride levels. 5,10,11,38,39 However, Ang II can stimulate synthesis or lysis of fat tissue, depending on the experimental conditions. 5,40 -42 On the other hand, as pointed out above, many studies have shown that Ang-(1-7) can counterregulate Ang II actions and participate in the ACE inhibitor effects.…”

Section: Santos Et Al Ang-(1-7) Improves Lipid and Glucose Metabolismmentioning

confidence: 99%

Improved Lipid and Glucose Metabolism in Transgenic Rats With Increased Circulating Angiotensin-(1-7)

Santos

Braga

Mario

et al. 2010

ATVB

146

121

View full text Add to dashboard Cite

Objective-Obesity and diabetes remain among the world's most pervasive health problems. Although the importance of angiotensin II for metabolic regulation is well documented, the role of the angiotensin-(1-7)/Mas axis in this process is poorly understood. The aim of this study was to evaluate the effect of increased angiotensin-(1-7) plasma levels in lipid and glucose metabolism using transgenic rats that express an angiotensin-(1-7)-releasing fusion protein, TGR(A1-7)3292 (TGR). Methods and Results-The increased angiotensin-(1-7) levels in TGR induced enhanced glucose tolerance, insulin sensitivity, and insulin-stimulated glucose uptake. In addition, TGR presented decreased triglycerides and cholesterol levels, as well as a significant decrease in abdominal fat mass, despite normal food intake. These alterations were accompanied by a marked decrease of angiotensinogen expression and increased Akt in adipose tissue. Furthermore, augmented plasma levels and expression in adipose tissue was observed for adiponectin. Accordingly, angiotensin-(1-7) stimulation increased adiponectin production by primary adipocyte culture, which was blocked by the Mas antagonist A779. Circulating insulin and muscle glycogen content were not altered in TGR. Conclusion-These

show abstract

“…The results of this study on fat mass and body weight are interesting when compared with a number of recent publications that have also studied the effects of ACE inhibition in rats over a range of ages. Two very recent studies 41,42 have shown that body weight and fat mass are reduced when ACE treatment started at a young age (birth and 6 weeks, respectively) in rats. Both these studies also reported that food intake was reduced (in contrast to our present study).…”

Section: Mechanisms Underlying the Reduction In Fat Massmentioning

confidence: 99%

Selective reduction in body fat mass and plasma leptin induced by angiotensin-converting enzyme inhibition in rats

et al. 2008

View full text Add to dashboard Cite

Objective: There is emerging evidence that angiotensin stimulates adipocyte differentiation and lipogenesis. This study tested the hypothesis that inhibition of angiotensin II by treatment with an angiotensin-converting enzyme inhibitor, perindopril, would reduce fat mass in rats. Design: After a 12-day baseline, rats were divided into two groups: one was untreated and the other received perindopril (1.2 mg kg À1 per day) in drinking water for 26 days. Subjects: In total, 16 male Sprague-Dawley rats aged 10 weeks at the start of the study. Measurements: Plasma leptin was measured in samples collected at baseline, half-way through and at the end of treatment. Body weight, food and water intake were measured daily throughout the experiment. Body fat mass, bone and lean mass were determined by dual energy X-ray absorptiometry (DEXA) at the end of the treatment period. Results: Daily food intake was the same in both groups throughout the study. By the end of treatment, animals receiving perindopril showed a modest reduction in weight gain relative to the untreated animals (62.4 ± 5.0 g vs 73.0 ± 4.0 g; Po0.05). DEXA analysis showed that body composition was greatly altered and the perindopril-treated group had 26% less body fat mass than the untreated group (61.0 ± 5.2 g vs 44.4 ± 4.2 g; Po0.01). The reduction in body fat mass was correlated with reductions in the weight of both the epididymal and retroperitoneal fat pads (Po0.001). Similarly, plasma leptin was reduced by perindopril treatment (4.64 ± 0.56 ng ml À1 ) compared to the untreated group (8.27 ± 1.03 ng ml À1 ; Po0.001). In contrast, there were no differences in lean or bone mass between the two groups. Conclusion: Oral treatment with perindopril selectively reduced body fat mass without influencing daily food intake. In contrast, there were no differences in lean or bone mass between the two groups.

show abstract

Effect of angiotensin converting enzyme inhibitor enalapril on body weight and composition in young rats

Cited by 51 publications

References 38 publications

Combination of Captopril and Allopurinol Retards Fructose-Induced Metabolic Syndrome

Combination of Captopril and Allopurinol Retards Fructose-Induced Metabolic Syndrome

Improved Lipid and Glucose Metabolism in Transgenic Rats With Increased Circulating Angiotensin-(1-7)

Selective reduction in body fat mass and plasma leptin induced by angiotensin-converting enzyme inhibition in rats

Contact Info

Product

Resources

About